Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a research note on Tuesday, February 25th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Cytosorbents currently has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Price Performance

Shares of NASDAQ CTSO opened at $1.13 on Tuesday. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $1.61. The firm has a fifty day simple moving average of $1.07 and a 200 day simple moving average of $1.05. The company has a market capitalization of $61.79 million, a PE ratio of -3.14 and a beta of 0.78. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

Institutional Investors Weigh In On Cytosorbents

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its stake in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares in the last quarter. Skylands Capital LLC increased its stake in Cytosorbents by 1.0% in the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after purchasing an additional 26,195 shares in the last quarter. Millennium Management LLC bought a new stake in Cytosorbents in the fourth quarter valued at $30,000. Northern Trust Corp grew its holdings in shares of Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after buying an additional 16,701 shares during the last quarter. Finally, Avenir Corp grew its holdings in shares of Cytosorbents by 4.0% during the fourth quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock valued at $2,815,000 after buying an additional 118,387 shares during the last quarter. 32.87% of the stock is owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.